Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Neutral
- Symbol (ENIA)
- Company Enel Américas S.A.
- Price $4.81
- Changes Percentage (0%)
- Change -$0
- Day Low $4.73
- Day High $5.09
- Year High $7.32
Enel Américas S.A., together with its subsidiaries, explores, develops, operates, generates, transfers, transforms, distributes, and sells electricity using hydroelectric and thermal energy sources in Argentina, Brazil, Colombia, and Peru. As of December 31, 2020, it had 11,269 megawatts of installed generation capacity and 25.6 million distribution customers. The company was formerly known as Enersis Américas S.A. and changed its name to Enel Américas S.A. in December 2016. Enel Américas S.A. was founded in 1889 and is headquartered in Santiago, Chile. Enel Américas S.A. operates as a subsidiary of Enel S.p.A.
- Last Earnings 05/02/2022
- Ex-Dividend for 5/16 Dividend 05/24/2022
- Dividend Payable 06/09/2022
- Today N/A
- Next Earnings (Estimated) 08/04/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.45
- Trailing P/E Ratio 10.688888888889
- Forward P/E Ratio 10.688888888889
- P/E Growth 10.688888888889
- Net Income $1.13 B
Income Statement
Quarterly
Annual
Latest News of ENIA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Palma Development tops out Serenia Living development in Dubai
Palma Development achieves a construction milestone by topping out Serenia Living, a luxury beachfront project in Dubai. The development consists of four towers with 226 exclusive apartments, offering...
By Yahoo! Finance | 2 days ago -
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials
AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment....
By Yahoo! Finance | 1 week ago -
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints
Bristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%....
By MarketWatch | 1 week ago
